374 related articles for article (PubMed ID: 27481651)
1. The genomic landscape of breast cancer and its interaction with host immunity.
Luen S; Virassamy B; Savas P; Salgado R; Loi S
Breast; 2016 Oct; 29():241-50. PubMed ID: 27481651
[TBL] [Abstract][Full Text] [Related]
2. Advances in personalized cancer immunotherapy.
Kakimi K; Karasaki T; Matsushita H; Sugie T
Breast Cancer; 2017 Jan; 24(1):16-24. PubMed ID: 27000871
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.
Luen SJ; Savas P; Fox SB; Salgado R; Loi S
Pathology; 2017 Feb; 49(2):141-155. PubMed ID: 28049579
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives.
de la Cruz-Merino L; Chiesa M; Caballero R; Rojo F; Palazón N; Carrasco FH; Sánchez-Margalet V
Int Rev Cell Mol Biol; 2017; 331():1-53. PubMed ID: 28325210
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of Breast Cancer.
Criscitiello C; Curigliano G
Prog Tumor Res; 2015; 42():30-43. PubMed ID: 26377084
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine for metastatic breast cancer--limitations and solutions.
Arnedos M; Vicier C; Loi S; Lefebvre C; Michiels S; Bonnefoi H; Andre F
Nat Rev Clin Oncol; 2015 Dec; 12(12):693-704. PubMed ID: 26196250
[TBL] [Abstract][Full Text] [Related]
7. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
8. Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer.
Kudelova E; Smolar M; Holubekova V; Hornakova A; Dvorska D; Lucansky V; Koklesova L; Kudela E; Kubatka P
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499265
[TBL] [Abstract][Full Text] [Related]
9. Genomic characterization of metastatic breast cancers.
Bertucci F; Ng CKY; Patsouris A; Droin N; Piscuoglio S; Carbuccia N; Soria JC; Dien AT; Adnani Y; Kamal M; Garnier S; Meurice G; Jimenez M; Dogan S; Verret B; Chaffanet M; Bachelot T; Campone M; Lefeuvre C; Bonnefoi H; Dalenc F; Jacquet A; De Filippo MR; Babbar N; Birnbaum D; Filleron T; Le Tourneau C; André F
Nature; 2019 May; 569(7757):560-564. PubMed ID: 31118521
[TBL] [Abstract][Full Text] [Related]
10. Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer.
Yates LR; Desmedt C
Clin Cancer Res; 2017 Jun; 23(11):2630-2639. PubMed ID: 28572257
[TBL] [Abstract][Full Text] [Related]
11. Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer.
Safonov A; Jiang T; Bianchini G; Győrffy B; Karn T; Hatzis C; Pusztai L
Cancer Res; 2017 Jun; 77(12):3317-3324. PubMed ID: 28428277
[TBL] [Abstract][Full Text] [Related]
12. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
13. The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes.
Duechler M; Peczek L; Zuk K; Zalesna I; Jeziorski A; Czyz M
Immunobiology; 2014 Feb; 219(2):158-65. PubMed ID: 24091277
[TBL] [Abstract][Full Text] [Related]
14. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.
Ng CK; Schultheis AM; Bidard FC; Weigelt B; Reis-Filho JS
J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713166
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
Savas P; Salgado R; Denkert C; Sotiriou C; Darcy PK; Smyth MJ; Loi S
Nat Rev Clin Oncol; 2016 Apr; 13(4):228-41. PubMed ID: 26667975
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
18. Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer.
Braunstein LZ; Taghian AG
Semin Radiat Oncol; 2016 Jan; 26(1):9-16. PubMed ID: 26617205
[TBL] [Abstract][Full Text] [Related]
19. What to expect from high throughput genomics in metastatic breast cancers?
Onesti CE; Vicier C; André F
Breast; 2015 Nov; 24 Suppl 2():S19-22. PubMed ID: 26238439
[TBL] [Abstract][Full Text] [Related]
20. Mutation matters in precision medicine: A future to believe in.
Dey N; Williams C; Leyland-Jones B; De P
Cancer Treat Rev; 2017 Apr; 55():136-149. PubMed ID: 28371665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
